[go: up one dir, main page]

WO2007016372A3 - Methode servant a regenerer un systeme immunitaire - Google Patents

Methode servant a regenerer un systeme immunitaire Download PDF

Info

Publication number
WO2007016372A3
WO2007016372A3 PCT/US2006/029483 US2006029483W WO2007016372A3 WO 2007016372 A3 WO2007016372 A3 WO 2007016372A3 US 2006029483 W US2006029483 W US 2006029483W WO 2007016372 A3 WO2007016372 A3 WO 2007016372A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
ccr5δ32
hsc
subject
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/029483
Other languages
English (en)
Other versions
WO2007016372A2 (fr
Inventor
Mitchell J Ghen
Ramesh Roshan
Romin Roshan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eden Biotech Ltd
Original Assignee
Eden Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eden Biotech Ltd filed Critical Eden Biotech Ltd
Priority to CA002617108A priority Critical patent/CA2617108A1/fr
Priority to EP06813245A priority patent/EP1919489A4/fr
Priority to US11/997,069 priority patent/US20090202496A1/en
Priority to JP2008524210A priority patent/JP2009502176A/ja
Priority to BRPI0614919-7A priority patent/BRPI0614919A2/pt
Priority to AU2006275625A priority patent/AU2006275625A1/en
Publication of WO2007016372A2 publication Critical patent/WO2007016372A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007016372A3 publication Critical patent/WO2007016372A3/fr
Priority to GB0803704A priority patent/GB2446310A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On utilise une lignée cellulaire isolée et purifiée de cellules souches hématopoïétiques (HSC) incapables d'exprimer le récepteur CCR5 sur leur surface, ('cellules CCR5Δ32'), afin de régénérer le système immunitaire d'un individu et, en particulier, de traiter un sujet infecté par le virus de l'immunodéficience humaine (VIH). On met en application cette méthode par transplantation de CCR5Δ32 dans l'individu récepteur. Etant donné que les cellules immunes matures dérivées des cellules CCR5Δ32 ne peuvent pas exprimer les récepteurs fonctionnels CCR5, elles seront résistantes à l'infection par VIH ou d'autres pathogènes utilisant ce récepteur CCR5 pour infecter des cellules. Un mode de réalisation de l'invention consiste à administrer un régime nutritionnel au patient, ce qui permet d'optimiser les conditions de transplantation des cellules CCR5Δ32. Un autre mode de réalisation consiste à co-transplanter des cellules mésenchymateuses avec HSC, de façon à augmenter la croissance et le développement de HSC transplanté.
PCT/US2006/029483 2005-07-28 2006-07-27 Methode servant a regenerer un systeme immunitaire Ceased WO2007016372A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002617108A CA2617108A1 (fr) 2005-07-28 2006-07-27 Methode servant a regenerer un systeme immunitaire
EP06813245A EP1919489A4 (fr) 2005-07-28 2006-07-27 Methode servant a regenerer un systeme immunitaire
US11/997,069 US20090202496A1 (en) 2005-07-28 2006-07-27 Method for regenerating an immune system
JP2008524210A JP2009502176A (ja) 2005-07-28 2006-07-27 免疫系の再生方法
BRPI0614919-7A BRPI0614919A2 (pt) 2005-07-28 2006-07-27 método para regenerar um sistema imune
AU2006275625A AU2006275625A1 (en) 2005-07-28 2006-07-27 Method for regenerating an immune system
GB0803704A GB2446310A (en) 2005-07-28 2008-02-28 Method for regenerating an immune system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70307305P 2005-07-28 2005-07-28
US60/703,073 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007016372A2 WO2007016372A2 (fr) 2007-02-08
WO2007016372A3 true WO2007016372A3 (fr) 2008-01-31

Family

ID=37709223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029483 Ceased WO2007016372A2 (fr) 2005-07-28 2006-07-27 Methode servant a regenerer un systeme immunitaire

Country Status (9)

Country Link
US (1) US20090202496A1 (fr)
EP (1) EP1919489A4 (fr)
JP (1) JP2009502176A (fr)
KR (1) KR20080048463A (fr)
AU (1) AU2006275625A1 (fr)
BR (1) BRPI0614919A2 (fr)
CA (1) CA2617108A1 (fr)
GB (1) GB2446310A (fr)
WO (1) WO2007016372A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003681A1 (en) * 2006-06-28 2008-01-03 Mahalaxmi Gita Bangera Methods for altering cellular susceptibility to infection
AU2012275526A1 (en) * 2011-06-29 2014-01-16 Ronilu Development Corporation Prevention and treatment of HIV infection
WO2014151994A1 (fr) 2013-03-15 2014-09-25 Kambiz Shekdar Édition de génome a l'aide d'oligonucléotides effecteurs pour un traitement thérapeutique
US10918672B1 (en) 2016-04-07 2021-02-16 The Administrators Of The Tulane Educational Fund Small tissue CCR5−MSCs for treatment of HIV
US20210012288A1 (en) * 2019-07-11 2021-01-14 David Mroczka Method and system for guidance of artificial intelligence and human agent teaming
CN111996164A (zh) * 2020-09-10 2020-11-27 聊城市人民医院 一种间充质干细胞的无血清抗衰老培养基

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039642A1 (en) * 2001-07-18 2003-02-27 Medra, Inc. Embryonic stem cells, clinical applications and methods for expanding in vitro
WO2004013330A1 (fr) * 2002-07-26 2004-02-12 Consejo Superior De Investigaciones Científicas Constructions genetiques multifonctionnelles a capacite d'inhibition elevee de l'expression du ccr5 dans la surface cellulaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4117904B2 (ja) * 1996-03-01 2008-07-16 エーロスクレーン エッス．アー． Ｃ−ｃ ｃｋｒ−５，ｃｃ−ケモカインレセプタ、その誘導体及びこれらの利用
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
US6877574B2 (en) * 2001-09-14 2005-04-12 Massachusetts Institute Of Technology Modular robotic teaching tool
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039642A1 (en) * 2001-07-18 2003-02-27 Medra, Inc. Embryonic stem cells, clinical applications and methods for expanding in vitro
WO2004013330A1 (fr) * 2002-07-26 2004-02-12 Consejo Superior De Investigaciones Científicas Constructions genetiques multifonctionnelles a capacite d'inhibition elevee de l'expression du ccr5 dans la surface cellulaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AKKINA R. ET AL.: "siRNAs, Ribozymes and RNA Decoys in Modeling Stem Cell-based Gene Therapy for HIV/AIDS", ANTICANCER RESEARCH, vol. 23, no. 3A, May 2003 (2003-05-01), pages 1997 - 2005, XP008126129 *
ANDERSON J. ET AL.: "CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection", RETROVIROLOGY, vol. 2, no. 53, 18 August 2005 (2005-08-18), pages 1 - 11, XP008126128 *
BAI J. ET AL.: "Characterization of Anti-CCR5 Ribozyme-Transduced CD34+ Hematopoietic Progenitor Cells in Vitro and in a SCID-hu Mouse Model in Vivo", MOLECULAR THERAPY, vol. 1, no. 3, March 2000 (2000-03-01), pages 244 - 254, XP008101748 *
BAI J. ET AL.: "Multivalent Anti-CCR5 Ribozymes for Stem Cell-Based HIV Type 1 Gene Therapy", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 17, no. 5, 20 March 2001 (2001-03-20), pages 385 - 399, XP009134175 *
BANERJEA A. ET AL.: "Lentiviral Transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages", AIDS RESEARCH AND THERAPY, vol. 1, no. 2, 17 December 2004 (2004-12-17), pages 1 - 11, XP002548921 *
LI M.-J. ET AL.: "Long-Term Inhibition of HIV-1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TART Decoy", MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 12, no. 5, 22 August 2005 (2005-08-22), pages 900 - 909, XP005126653 *

Also Published As

Publication number Publication date
BRPI0614919A2 (pt) 2011-04-19
US20090202496A1 (en) 2009-08-13
AU2006275625A2 (en) 2008-05-01
JP2009502176A (ja) 2009-01-29
CA2617108A1 (fr) 2007-02-08
EP1919489A4 (fr) 2009-05-06
GB2446310A (en) 2008-08-06
GB0803704D0 (en) 2008-04-09
WO2007016372A2 (fr) 2007-02-08
AU2006275625A1 (en) 2007-02-08
KR20080048463A (ko) 2008-06-02
EP1919489A2 (fr) 2008-05-14

Similar Documents

Publication Publication Date Title
GB2446310A (en) Method for regenerating an immune system
WO2008150814A8 (fr) Procédés de production et d'utilisations de populations de cellules multipotentes, pluripotentes, différentiées et résistantes au vih
Romagnani et al. CD133+ renal stem cells always co-express CD24 in adult human kidney tissue
CN107254439A (zh) 增强自然杀伤细胞增殖和活性的方法
CN102317447A (zh) 用于筛选扩增的干细胞群的方法
Hens et al. The role of NK cells in HIV-1 protection: autologous, allogeneic or both?
Forrest et al. NK cell memory to cytomegalovirus: implications for vaccine development
Ni et al. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
Schweitzer et al. Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients
Castillo-Olivares et al. Detection of equine arteritis virus (EAV)-specific cytotoxic CD8+ T lymphocyte precursors from EAV-infected ponies
JP2002171966A5 (fr)
WO2002102971A3 (fr) Methodes d'utilisation de cellules souches hematopoietiques cultivees afin d'induire une tolerance immunologique
WO2007030820A3 (fr) Manipulation de cellules t regulatrices et de fonctions dc en ciblant des genes de neuritine a l'aide d'agonistes et d'antagonistes d'anticorps
Silk et al. Harnessing dendritic cells for the induction of transplantation tolerance
Gerstenkorn et al. The impact of cytomegalovirus serology for 7‐year graft survival in cadaveric kidney transplantation‐the Newcastle experience
Clerici et al. AIDS in Africa
夏凌辉 et al. Study on the level of CD4+ CD25+ T cells and aGVHD after HSCT
WO2008067126A3 (fr) Méthodes d'utilisation de cellules aldhbr pour compléter une transplantation de cellules souches
Madrigal Toscano Cough, wheezing and respiratory failure: case report
Fox et al. Acquired Immunodeficiency Syndrome--A Review and Update: History, Characteristics of Human Immunodeficiency Virus Infection, Its Replication, Biologic Factors, and Pathogenicity
王亚东 Significance of natural killer cell G2D expression and activation in patients with different immune status of chronic hepatitis B virus infection
ZHANG et al. In vitro infection of tree shrew immunocytes with human immunodeficiency virus type Ⅰ
Sell et al. Xenobanking for Organ Preservation
Bernal et al. An HIV-positive man with spontaneous development of a thyroid tumor
Bonneau HIV-1 Tat: Its Effects on CD34+ Hematopoietic Human Stem Cell Differentiation and Survival

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2617108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008524210

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087004442

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006275625

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 0803704

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20060727

WWE Wipo information: entry into national phase

Ref document number: 0803704.6

Country of ref document: GB

Ref document number: 2006813245

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006275625

Country of ref document: AU

Date of ref document: 20060727

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11997069

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0614919

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080128